Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2019 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the...
May 09, 2019 07:05 ET | Source: Myriad Genetics, Inc.

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

SALT LAKE CITY, May 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict® test (EPclin) identifies women...
May 07, 2019 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 PercentThird-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad...
May 01, 2019 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide...
May 01, 2019 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two...
April 30, 2019 11:17 ET | Source: Myriad Genetics, Inc.

EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

SALT LAKE CITY, April 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers has...
April 23, 2019 16:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and...
April 23, 2019 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present...
April 17, 2019 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to...
April 09, 2019 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has submitted the first module of its premarket...